Selected publications
-
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.
The Lancet Oncology.
2016
Academic Article
GET IT
Times cited: 83 -
Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomized controlled trial.
Journal of Clinical Oncology.
2015
Academic Article
GET IT
Times cited: 118 -
Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: A report from the children's oncology group.
Journal of Clinical Oncology.
2012
Academic Article
GET IT
Times cited: 114 -
Dose-intensified compared with standard chemotherapy for nonmetastatic ewing sarcoma family of tumors: A children's oncology group study.
Journal of Clinical Oncology.
2009
Academic Article
GET IT
Times cited: 184 - In reply [10]. Journal of Clinical Oncology. 2007 Information Resource GET IT
-
Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group.
Journal of Clinical Oncology.
2007
Academic Article
GET IT
Times cited: 77 -
Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric oncology group/children's cancer group phase II study 9457 - A report from the children's oncology group.
Journal of Clinical Oncology.
2006
Academic Article
GET IT
Times cited: 78